TY - JOUR
T1 - Centiloid scaling for quantification of brain amyloid with [ 18 F]flutemetamol using multiple processing methods
AU - Battle, Mark R.
AU - Pillay, Lovena Chedumbarum
AU - Lowe, Val J.
AU - Knopman, David
AU - Kemp, Bradley
AU - Rowe, Christopher C.
AU - Doré, Vincent
AU - Villemagne, Victor L.
AU - Buckley, Christopher J.
N1 - Funding Information:
VJL is a consultant for Bayer Pharma, Piramal Imaging, and receives research support from GE Healthcare, AVID Radiopharmaceuticals, the NIH, the Dekelboum Family Foundation, and the Liston Family Foundation. DK serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is a clinical investigator for Biogen, TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer’s Disease Cooperative Study; and receives research support from the NIH. CCR has received research grants for imaging in dementia from Bayer-Schering Pharma, Avid Radiopharmaceuticals, GE Healthcare, Piramal, Astra Zeneca, and Navidea. He has been a consultant or paid speaker at sponsored conference sessions for Bayer-Schering Pharma, Piramal, GE Healthcare, Astra Zeneca, Roche, and Janssen. VLV has been a consultant or paid speaker at sponsored conference sessions for Bayer-Schering Pharma, Piramal, GE Healthcare, Astra Zeneca, and Novartis. MRB, CJB and LCP are employees of GE Healthcare. The remaining authors (BK and VD) have nothing to declare.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018
Y1 - 2018
N2 - Introduction: A standardised method for quantifying β-amyloid PET tracers would allow comparison across different tracers and different sites. The development of the Centiloid scale has aimed to achieve this, applying a common scale to better aid the diagnosis and prognosis of Alzheimer’s disease (AD) and to monitor anti-amyloid therapeutic interventions. Here, we apply the Centiloid method to [ 18 F]flutemetamol and [ 11 C]PiB (PiB, Pittsburgh compound B) PET images and derive the scaling factor to express their binding in Centiloids. Methods: Paired PiB and [ 18 F]flutemetamol scans for 74 subjects, including 24 young healthy controls (37 ± 5 years), were analysed using the standard Centiloid method. The same subjects were also analysed using PMOD- and FSL-based pipelines as well as SPM8. Test-retest analysis of 10 AD subjects was also performed with each pipeline. Results: The standard uptake value ratios (SUVR), determined using the standard SPM8 Centiloid process, showed a strong correlation between [ 18 F]flutemetamol (Flute) and PiB binding (SUVR-Flute = 0.77 × SUVR-PiB + 0.22, R 2 = 0.96). Application of the standard Centiloid process allowed the calculation of a direct conversion equation for SUVR-Flute to Centiloid units (CL) (CL = (121.42*SUVR-Flute) − 121.16). Analysis of the data via the two alternate Centiloid pipelines allowed us to derive standardised, SPM8-equivalent equations for both PMOD (CL = (115.24*SUVR-Flute) − 107.86) and FSL (CL = (120.32*SUVR-Flute) − 112.75) respectively. Test-retest analysis of 10 AD subjects showed an approximate 2% difference for each pipeline. Conclusions: [ 18 F]flutemetamol data can now be expressed in Centiloid units, enhancing its utility in clinical and research applications for β-amyloid imaging. The standard Centiloid method also demonstrates that [ 18 F]flutemetamol has favourable performance compared with PiB and other β-amyloid tracers. Test-retest difference averaged 2%, with no difference between image processing pipelines. Centiloid scaling is robust and can be implemented on a number of platforms.
AB - Introduction: A standardised method for quantifying β-amyloid PET tracers would allow comparison across different tracers and different sites. The development of the Centiloid scale has aimed to achieve this, applying a common scale to better aid the diagnosis and prognosis of Alzheimer’s disease (AD) and to monitor anti-amyloid therapeutic interventions. Here, we apply the Centiloid method to [ 18 F]flutemetamol and [ 11 C]PiB (PiB, Pittsburgh compound B) PET images and derive the scaling factor to express their binding in Centiloids. Methods: Paired PiB and [ 18 F]flutemetamol scans for 74 subjects, including 24 young healthy controls (37 ± 5 years), were analysed using the standard Centiloid method. The same subjects were also analysed using PMOD- and FSL-based pipelines as well as SPM8. Test-retest analysis of 10 AD subjects was also performed with each pipeline. Results: The standard uptake value ratios (SUVR), determined using the standard SPM8 Centiloid process, showed a strong correlation between [ 18 F]flutemetamol (Flute) and PiB binding (SUVR-Flute = 0.77 × SUVR-PiB + 0.22, R 2 = 0.96). Application of the standard Centiloid process allowed the calculation of a direct conversion equation for SUVR-Flute to Centiloid units (CL) (CL = (121.42*SUVR-Flute) − 121.16). Analysis of the data via the two alternate Centiloid pipelines allowed us to derive standardised, SPM8-equivalent equations for both PMOD (CL = (115.24*SUVR-Flute) − 107.86) and FSL (CL = (120.32*SUVR-Flute) − 112.75) respectively. Test-retest analysis of 10 AD subjects showed an approximate 2% difference for each pipeline. Conclusions: [ 18 F]flutemetamol data can now be expressed in Centiloid units, enhancing its utility in clinical and research applications for β-amyloid imaging. The standard Centiloid method also demonstrates that [ 18 F]flutemetamol has favourable performance compared with PiB and other β-amyloid tracers. Test-retest difference averaged 2%, with no difference between image processing pipelines. Centiloid scaling is robust and can be implemented on a number of platforms.
UR - http://www.scopus.com/inward/record.url?scp=85058847890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058847890&partnerID=8YFLogxK
U2 - 10.1186/s13550-018-0456-7
DO - 10.1186/s13550-018-0456-7
M3 - Article
AN - SCOPUS:85058847890
SN - 2191-219X
VL - 8
JO - EJNMMI Research
JF - EJNMMI Research
M1 - 107
ER -